TrialRMD open2022

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study.

Désirée van der Heijde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.